STOCK TITAN

[Form 4] Full House Resorts, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

BioSig Technologies (BSGM) has called a virtual special meeting to seek shareholder approval for several highly dilutive and governance-altering actions tied to its recently closed acquisition of Streamex Exchange Corp.

  • Proposal 1: Ratify issuance of ≈109.1 million common shares (plus one Super Voting Preferred share) to Streamex sellers. If approved, Streamex holders would ultimately control 75% of BioSig’s fully-diluted equity; existing investors fall to 25%.
  • Proposal 2: Authorize stock underlying convertible debentures to YA II PN, Ltd.
  • Proposal 3: Add 10,359,211 shares to the 2023 LTIP (total 14,735,806).
  • Proposal 4: Permit issuance of ≥19.99% of outstanding shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
  • Proposal 5: Increase authorized common shares from 200 million to 500 million.
  • Proposal 6: Stagger the board into three classes.

The board unanimously recommends voting “FOR” all proposals. Quorum is one-third of voting power; most items need simple majority of votes cast, but the classified board requires majority of all outstanding shares. Risk disclosure highlights extensive dilution, regulatory uncertainty around Streamex’s gold-tokenization model, and integration challenges. Record date and meeting date remain blank pending SEC clearance.

BioSig Technologies (BSGM) ha convocato un'assemblea speciale virtuale per ottenere l'approvazione degli azionisti su diverse azioni altamente diluitive e modifiche di governance legate alla recente acquisizione di Streamex Exchange Corp.

  • Proposta 1: Ratificare l'emissione di circa 109,1 milioni di azioni ordinarie (più un'azione preferenziale Super Voting) ai venditori di Streamex. Se approvata, i detentori di Streamex controllerebbero il 75% del capitale azionario completamente diluito di BioSig; gli investitori attuali scenderebbero al 25%.
  • Proposta 2: Autorizzare le azioni sottostanti le obbligazioni convertibili a favore di YA II PN, Ltd.
  • Proposta 3: Aggiungere 10.359.211 azioni al LTIP 2023 (totale 14.735.806).
  • Proposta 4: Consentire l'emissione di ≥19,99% delle azioni in circolazione nell'ambito di un Accordo di Acquisto Azionario Standby (SEPA) con Yorkville.
  • Proposta 5: Aumentare le azioni ordinarie autorizzate da 200 milioni a 500 milioni.
  • Proposta 6: Suddividere il consiglio di amministrazione in tre classi.

Il consiglio raccomanda all'unanimità di votare “A FAVORE” di tutte le proposte. Il quorum è pari a un terzo del potere di voto; la maggior parte delle proposte richiede la maggioranza semplice dei voti espressi, mentre per il consiglio classificato è necessaria la maggioranza di tutte le azioni in circolazione. La dichiarazione di rischio evidenzia un'ampia diluizione, incertezze normative riguardo al modello di tokenizzazione dell'oro di Streamex e le sfide di integrazione. La data di registrazione e la data dell'assemblea sono ancora da definire in attesa dell'approvazione della SEC.

BioSig Technologies (BSGM) ha convocado una junta especial virtual para solicitar la aprobación de los accionistas sobre varias acciones altamente dilutivas y cambios en la gobernanza vinculados a su reciente adquisición de Streamex Exchange Corp.

  • Propuesta 1: Ratificar la emisión de aproximadamente 109,1 millones de acciones comunes (más una acción preferente con súper voto) a los vendedores de Streamex. Si se aprueba, los titulares de Streamex controlarían el 75% del capital totalmente diluido de BioSig; los inversores actuales disminuirían al 25%.
  • Propuesta 2: Autorizar las acciones subyacentes a los bonos convertibles a favor de YA II PN, Ltd.
  • Propuesta 3: Añadir 10.359.211 acciones al LTIP 2023 (total 14.735.806).
  • Propuesta 4: Permitir la emisión de ≥19,99% de las acciones en circulación bajo un Acuerdo de Compra de Acciones en Espera (SEPA) con Yorkville.
  • Propuesta 5: Incrementar las acciones comunes autorizadas de 200 millones a 500 millones.
  • Propuesta 6: Dividir la junta directiva en tres clases.

La junta recomienda por unanimidad votar “A FAVOR” de todas las propuestas. El quórum es un tercio del poder de voto; la mayoría de las propuestas requieren mayoría simple de los votos emitidos, pero la junta clasificada requiere mayoría de todas las acciones en circulación. La divulgación de riesgos destaca una dilución extensa, incertidumbre regulatoria sobre el modelo de tokenización de oro de Streamex y desafíos de integración. La fecha de registro y la fecha de la reunión están pendientes de aprobación de la SEC.

BioSig Technologies(BSGM)는 최근 완료한 Streamex Exchange Corp. 인수와 관련하여 주주 승인을 받기 위해 가상 특별 회의를 소집했습니다. 이번 안건들은 대규모 희석과 거버넌스 변경을 포함합니다.

  • 제안 1: Streamex 매도자에게 약 1억 910만 주의 보통주(및 1주의 슈퍼 투표 우선주) 발행을 승인합니다. 승인 시 Streamex 보유자는 BioSig 희석 후 지분의 75%를 보유하며 기존 투자자는 25%로 감소합니다.
  • 제안 2: YA II PN, Ltd.에 대한 전환사채 기초 주식 발행 승인.
  • 제안 3: 2023년 장기 인센티브 계획(LTIP)에 10,359,211주 추가(총 14,735,806주).
  • 제안 4: Yorkville과의 대기 주식 매입 계약(SEPA)에 따라 발행 주식의 ≥19.99% 발행 허용.
  • 제안 5: 승인된 보통주 수를 2억 주에서 5억 주로 증가.
  • 제안 6: 이사회를 3개 계층으로 나누기.

이사회는 만장일치로 모든 제안에 대해 “찬성” 투표를 권고합니다. 정족수는 의결권의 3분의 1이며, 대부분 안건은 출석 의결권 과반수 찬성 필요하지만 계층화된 이사회는 전체 발행 주식 과반수 찬성이 필요합니다. 위험 고지에는 광범위한 희석, Streamex의 금 토큰화 모델에 대한 규제 불확실성, 통합 문제 등이 강조되었습니다. 기록일과 회의일은 SEC 승인 대기 중으로 아직 미정입니다.

BioSig Technologies (BSGM) a convoqué une assemblée spéciale virtuelle pour obtenir l'approbation des actionnaires concernant plusieurs actions très dilutives et des modifications de gouvernance liées à son acquisition récente de Streamex Exchange Corp.

  • Proposition 1 : Ratifier l'émission d'environ 109,1 millions d'actions ordinaires (plus une action préférentielle à super vote) aux vendeurs de Streamex. En cas d'approbation, les détenteurs de Streamex contrôleraiennt finalement 75 % du capital entièrement dilué de BioSig ; les investisseurs actuels tomberaient à 25 %.
  • Proposition 2 : Autoriser les actions sous-jacentes aux obligations convertibles à YA II PN, Ltd.
  • Proposition 3 : Ajouter 10 359 211 actions au LTIP 2023 (total 14 735 806).
  • Proposition 4 : Permettre l'émission d'au moins 19,99 % des actions en circulation dans le cadre d'un accord d'achat d'actions en attente (SEPA) avec Yorkville.
  • Proposition 5 : Augmenter le nombre d'actions ordinaires autorisées de 200 millions à 500 millions.
  • Proposition 6 : Fractionner le conseil d'administration en trois classes.

Le conseil d'administration recommande à l'unanimité de voter « POUR » toutes les propositions. Le quorum est d'un tiers des droits de vote ; la plupart des points nécessitent une majorité simple des voix exprimées, mais le conseil classifié requiert la majorité de toutes les actions en circulation. La divulgation des risques souligne une dilution importante, une incertitude réglementaire concernant le modèle de tokenisation de l'or de Streamex et des défis d'intégration. La date d'enregistrement et la date de la réunion restent à définir en attente de l'approbation de la SEC.

BioSig Technologies (BSGM) hat eine virtuelle Sonderversammlung einberufen, um die Zustimmung der Aktionäre zu mehreren stark verwässernden und governance-verändernden Maßnahmen im Zusammenhang mit der kürzlich abgeschlossenen Übernahme von Streamex Exchange Corp. einzuholen.

  • Vorschlag 1: Genehmigung der Ausgabe von ca. 109,1 Millionen Stammaktien (plus einer Super-Voting-Vorzugsaktie) an die Verkäufer von Streamex. Bei Zustimmung würden die Streamex-Inhaber letztlich 75 % des vollständig verwässerten Eigenkapitals von BioSig kontrollieren; die bestehenden Investoren würden auf 25 % sinken.
  • Vorschlag 2: Genehmigung der Aktien, die den wandelbaren Schuldverschreibungen an YA II PN, Ltd. zugrunde liegen.
  • Vorschlag 3: Hinzufügung von 10.359.211 Aktien zum LTIP 2023 (insgesamt 14.735.806).
  • Vorschlag 4: Erlaubnis zur Ausgabe von ≥19,99 % der ausstehenden Aktien im Rahmen einer Standby Equity Purchase Agreement (SEPA) mit Yorkville.
  • Vorschlag 5: Erhöhung der genehmigten Stammaktien von 200 Millionen auf 500 Millionen.
  • Vorschlag 6: Aufteilung des Vorstands in drei Klassen.

Der Vorstand empfiehlt einstimmig, allen Vorschlägen „ZUSTIMMEN“ zu stimmen. Das Quorum beträgt ein Drittel der Stimmrechte; die meisten Punkte erfordern eine einfache Mehrheit der abgegebenen Stimmen, für den gestaffelten Vorstand ist jedoch die Mehrheit aller ausstehenden Aktien erforderlich. Die Risikooffenlegung weist auf umfangreiche Verwässerungen, regulatorische Unsicherheiten bezüglich des Gold-Tokenisierungsmodells von Streamex und Integrationsherausforderungen hin. Das Stichtags- und Versammlungsdatum stehen noch aus, da die SEC noch zustimmen muss.

Positive
  • Diversification: Streamex acquisition adds a second operating segment focused on tokenized real-world assets, potentially expanding revenue sources.
  • Liquidity backstop: SEPA and Yorkville convertible debentures provide flexible financing options to fund integration and growth.
  • Plan expansion: Added LTIP shares may help attract and retain key talent needed to execute new strategy.
Negative
  • Severe dilution: Streamex holders will own up to 75% post-approval; authorized shares jump to 500 million.
  • Governance entrenchment: Creation of a classified board and one Super Voting Preferred share diminishes minority influence.
  • Regulatory uncertainty: Streamex’s gold-tokenization business faces untested securities and commodities oversight.
  • Financing overhang: Yorkville debentures and SEPA could introduce continuous selling pressure.
  • Execution risk: Integration of a start-up with going-concern doubts into a medical-device company adds complexity and operational strain.

Insights

TL;DR: Transaction delivers new business line but hands 75 % control to Streamex, triggers massive dilution, and relies on additional Yorkville financing.

The share issuance, SEPA and debentures could more than triple BioSig’s float, pressuring price and complicating future capital raises. While diversification into tokenized gold may expand TAM, the business is pre-revenue and faces heavy regulatory and liquidity risks. Increasing authorized shares to 500 million and adopting a classified board reduce shareholder leverage going forward. Net impact skews negative for current holders.

TL;DR: Proposals shift power from existing investors to new insiders and entrench the board.

The Super Voting Preferred share and staggered board limit accountability. Combined with Yorkville facilities, management gains latitude to issue large blocks without further approval. Shareholders must weigh potential growth against reduced influence and sustained dilution risk.

BioSig Technologies (BSGM) ha convocato un'assemblea speciale virtuale per ottenere l'approvazione degli azionisti su diverse azioni altamente diluitive e modifiche di governance legate alla recente acquisizione di Streamex Exchange Corp.

  • Proposta 1: Ratificare l'emissione di circa 109,1 milioni di azioni ordinarie (più un'azione preferenziale Super Voting) ai venditori di Streamex. Se approvata, i detentori di Streamex controllerebbero il 75% del capitale azionario completamente diluito di BioSig; gli investitori attuali scenderebbero al 25%.
  • Proposta 2: Autorizzare le azioni sottostanti le obbligazioni convertibili a favore di YA II PN, Ltd.
  • Proposta 3: Aggiungere 10.359.211 azioni al LTIP 2023 (totale 14.735.806).
  • Proposta 4: Consentire l'emissione di ≥19,99% delle azioni in circolazione nell'ambito di un Accordo di Acquisto Azionario Standby (SEPA) con Yorkville.
  • Proposta 5: Aumentare le azioni ordinarie autorizzate da 200 milioni a 500 milioni.
  • Proposta 6: Suddividere il consiglio di amministrazione in tre classi.

Il consiglio raccomanda all'unanimità di votare “A FAVORE” di tutte le proposte. Il quorum è pari a un terzo del potere di voto; la maggior parte delle proposte richiede la maggioranza semplice dei voti espressi, mentre per il consiglio classificato è necessaria la maggioranza di tutte le azioni in circolazione. La dichiarazione di rischio evidenzia un'ampia diluizione, incertezze normative riguardo al modello di tokenizzazione dell'oro di Streamex e le sfide di integrazione. La data di registrazione e la data dell'assemblea sono ancora da definire in attesa dell'approvazione della SEC.

BioSig Technologies (BSGM) ha convocado una junta especial virtual para solicitar la aprobación de los accionistas sobre varias acciones altamente dilutivas y cambios en la gobernanza vinculados a su reciente adquisición de Streamex Exchange Corp.

  • Propuesta 1: Ratificar la emisión de aproximadamente 109,1 millones de acciones comunes (más una acción preferente con súper voto) a los vendedores de Streamex. Si se aprueba, los titulares de Streamex controlarían el 75% del capital totalmente diluido de BioSig; los inversores actuales disminuirían al 25%.
  • Propuesta 2: Autorizar las acciones subyacentes a los bonos convertibles a favor de YA II PN, Ltd.
  • Propuesta 3: Añadir 10.359.211 acciones al LTIP 2023 (total 14.735.806).
  • Propuesta 4: Permitir la emisión de ≥19,99% de las acciones en circulación bajo un Acuerdo de Compra de Acciones en Espera (SEPA) con Yorkville.
  • Propuesta 5: Incrementar las acciones comunes autorizadas de 200 millones a 500 millones.
  • Propuesta 6: Dividir la junta directiva en tres clases.

La junta recomienda por unanimidad votar “A FAVOR” de todas las propuestas. El quórum es un tercio del poder de voto; la mayoría de las propuestas requieren mayoría simple de los votos emitidos, pero la junta clasificada requiere mayoría de todas las acciones en circulación. La divulgación de riesgos destaca una dilución extensa, incertidumbre regulatoria sobre el modelo de tokenización de oro de Streamex y desafíos de integración. La fecha de registro y la fecha de la reunión están pendientes de aprobación de la SEC.

BioSig Technologies(BSGM)는 최근 완료한 Streamex Exchange Corp. 인수와 관련하여 주주 승인을 받기 위해 가상 특별 회의를 소집했습니다. 이번 안건들은 대규모 희석과 거버넌스 변경을 포함합니다.

  • 제안 1: Streamex 매도자에게 약 1억 910만 주의 보통주(및 1주의 슈퍼 투표 우선주) 발행을 승인합니다. 승인 시 Streamex 보유자는 BioSig 희석 후 지분의 75%를 보유하며 기존 투자자는 25%로 감소합니다.
  • 제안 2: YA II PN, Ltd.에 대한 전환사채 기초 주식 발행 승인.
  • 제안 3: 2023년 장기 인센티브 계획(LTIP)에 10,359,211주 추가(총 14,735,806주).
  • 제안 4: Yorkville과의 대기 주식 매입 계약(SEPA)에 따라 발행 주식의 ≥19.99% 발행 허용.
  • 제안 5: 승인된 보통주 수를 2억 주에서 5억 주로 증가.
  • 제안 6: 이사회를 3개 계층으로 나누기.

이사회는 만장일치로 모든 제안에 대해 “찬성” 투표를 권고합니다. 정족수는 의결권의 3분의 1이며, 대부분 안건은 출석 의결권 과반수 찬성 필요하지만 계층화된 이사회는 전체 발행 주식 과반수 찬성이 필요합니다. 위험 고지에는 광범위한 희석, Streamex의 금 토큰화 모델에 대한 규제 불확실성, 통합 문제 등이 강조되었습니다. 기록일과 회의일은 SEC 승인 대기 중으로 아직 미정입니다.

BioSig Technologies (BSGM) a convoqué une assemblée spéciale virtuelle pour obtenir l'approbation des actionnaires concernant plusieurs actions très dilutives et des modifications de gouvernance liées à son acquisition récente de Streamex Exchange Corp.

  • Proposition 1 : Ratifier l'émission d'environ 109,1 millions d'actions ordinaires (plus une action préférentielle à super vote) aux vendeurs de Streamex. En cas d'approbation, les détenteurs de Streamex contrôleraiennt finalement 75 % du capital entièrement dilué de BioSig ; les investisseurs actuels tomberaient à 25 %.
  • Proposition 2 : Autoriser les actions sous-jacentes aux obligations convertibles à YA II PN, Ltd.
  • Proposition 3 : Ajouter 10 359 211 actions au LTIP 2023 (total 14 735 806).
  • Proposition 4 : Permettre l'émission d'au moins 19,99 % des actions en circulation dans le cadre d'un accord d'achat d'actions en attente (SEPA) avec Yorkville.
  • Proposition 5 : Augmenter le nombre d'actions ordinaires autorisées de 200 millions à 500 millions.
  • Proposition 6 : Fractionner le conseil d'administration en trois classes.

Le conseil d'administration recommande à l'unanimité de voter « POUR » toutes les propositions. Le quorum est d'un tiers des droits de vote ; la plupart des points nécessitent une majorité simple des voix exprimées, mais le conseil classifié requiert la majorité de toutes les actions en circulation. La divulgation des risques souligne une dilution importante, une incertitude réglementaire concernant le modèle de tokenisation de l'or de Streamex et des défis d'intégration. La date d'enregistrement et la date de la réunion restent à définir en attente de l'approbation de la SEC.

BioSig Technologies (BSGM) hat eine virtuelle Sonderversammlung einberufen, um die Zustimmung der Aktionäre zu mehreren stark verwässernden und governance-verändernden Maßnahmen im Zusammenhang mit der kürzlich abgeschlossenen Übernahme von Streamex Exchange Corp. einzuholen.

  • Vorschlag 1: Genehmigung der Ausgabe von ca. 109,1 Millionen Stammaktien (plus einer Super-Voting-Vorzugsaktie) an die Verkäufer von Streamex. Bei Zustimmung würden die Streamex-Inhaber letztlich 75 % des vollständig verwässerten Eigenkapitals von BioSig kontrollieren; die bestehenden Investoren würden auf 25 % sinken.
  • Vorschlag 2: Genehmigung der Aktien, die den wandelbaren Schuldverschreibungen an YA II PN, Ltd. zugrunde liegen.
  • Vorschlag 3: Hinzufügung von 10.359.211 Aktien zum LTIP 2023 (insgesamt 14.735.806).
  • Vorschlag 4: Erlaubnis zur Ausgabe von ≥19,99 % der ausstehenden Aktien im Rahmen einer Standby Equity Purchase Agreement (SEPA) mit Yorkville.
  • Vorschlag 5: Erhöhung der genehmigten Stammaktien von 200 Millionen auf 500 Millionen.
  • Vorschlag 6: Aufteilung des Vorstands in drei Klassen.

Der Vorstand empfiehlt einstimmig, allen Vorschlägen „ZUSTIMMEN“ zu stimmen. Das Quorum beträgt ein Drittel der Stimmrechte; die meisten Punkte erfordern eine einfache Mehrheit der abgegebenen Stimmen, für den gestaffelten Vorstand ist jedoch die Mehrheit aller ausstehenden Aktien erforderlich. Die Risikooffenlegung weist auf umfangreiche Verwässerungen, regulatorische Unsicherheiten bezüglich des Gold-Tokenisierungsmodells von Streamex und Integrationsherausforderungen hin. Das Stichtags- und Versammlungsdatum stehen noch aus, da die SEC noch zustimmen muss.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LEE DANIEL R

(Last) (First) (Middle)
C/O FULL HOUSE RESORTS, INC.
1980 FESTIVAL PLAZA DRIVE, SUITE 680

(Street)
LAS VEGAS NV 89135

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
FULL HOUSE RESORTS INC [ FLL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 07/23/2025 X 184,200 A $4.75 1,260,918 D
Common Stock 145,735 I By trust
Common Stock 317,145 I By subtrust
Common Stock 15,926 I As custodian for daughter
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Put Option (obligation to purchase)(1) $4.75 07/23/2025 X 184,200 06/13/2025 06/26/2026 Common Stock 184,200 $0 0 D
Call Option (right to buy)(1) $4.75 07/23/2025 E 184,200 06/13/2025 06/13/2026 Common Stock 184,200 $0 0 D
Explanation of Responses:
1. In a private transaction dated June 13, 2025, Mr. Lee purchased 92,100 shares of common stock of Full House Resorts, Inc. (the "Company") directly and 184,200 shares of the Company's common stock indirectly through a subtrust for the benefit of Mr. Lee's children, both at a purchase price of $4.75 per share, and obtained a call option to purchase 184,200 additional shares of the Company's common stock at that same price. The call option expires on June 13, 2026. Seller also had the right to cause Mr. Lee to purchase the additional 184,200 shares at that same price if the closing price of the Company's common stock as reported by NASDAQ was at a price per share of $4.75 or greater on any day prior to June 13, 2026. On July 23, 2025, Seller exercised the right to cause Mr. Lee to purchase the additional 184,200 shares, and Mr. Lee purchased such shares pursuant to the obligation to purchase. There are no further shares related to the right to buy or obligation to purchase.
/s/ Lewis A. Fanger, Attorney-in-Fact 07/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why is BioSig (BSGM) issuing 109 million shares?

Those shares, plus one Super Voting Preferred share, constitute the purchase consideration for Streamex under Proposal 1.

How much will existing BSGM shareholders be diluted if all proposals pass?

Legacy holders drop to about 25% ownership; Streamex sellers capture roughly 75% of fully-diluted equity.

What change is proposed for BioSig’s authorized share count?

Proposal 5 seeks to raise the cap from 200 million to 500 million common shares.

What is the purpose of the SEPA with Yorkville?

Proposal 4 allows BioSig to sell up to 19.99% of outstanding stock to Yorkville as a standby equity source.

How will the board structure change?

Proposal 6 classifies directors into three staggered classes, each serving three-year terms, making board turnover more gradual.

Does the filing discuss specific financial results or earnings?

No; the preliminary proxy focuses on share issuances, governance changes and risk factors, not current earnings performance.
Full House Resor

NASDAQ:FLL

FLL Rankings

FLL Latest News

FLL Latest SEC Filings

FLL Stock Data

178.08M
33.51M
7.52%
47.06%
3.71%
Resorts & Casinos
Hotels & Motels
Link
United States
LAS VEGAS